FDA+ channel feed – Endpoints News

FDA+ channel feed

Operation Warp Speed for rare diseases: CBER leader says pilot is coming soon

3 years ago

Japan cancels 140M dose order for Novavax Covid vaccine amid 'lower than expected' demand

3 years ago

FDA hands down a partial hold for PhI/II trial of Blueprint’s CDK2 inhibitor

3 years ago

Still no green light for Phathom's gastrointestinal drugs after impurities found in batches

3 years ago

FDA advisors vote 8-5 in favor of GSK's Jemperli trial plan for rare rectal cancer

3 years ago

UK microcap faces partial clinical hold in mid-stage IPF trial

3 years ago

FDA commissioner floats ideas on how to better handle the pandemic

3 years ago

FDA assembles adcomm to review GSK's Jemperli trial plans in rectal cancer

3 years ago

Biden to tout pharma's defeat in State of the Union, call for $35 insulin for all

3 years ago

Updated: Biden's science team sees another mini-transition as Alondra Nelson departs

3 years ago

Sage, Biogen set their sights on a summer PDUFA deadline as zuranolone decision looms

3 years ago

FDA places hold on 4D Molecular’s Fabry gene therapy

3 years ago

Trodelvy notches a win in most common form of breast cancer

3 years ago

FDA approves GSK's anemia drug with safety warning — after batting back similar drugs

3 years ago

FDA axes requirement for positive Covid test before Paxlovid use

3 years ago

Pfizer brings Ibrance to new subset of breast cancer patients, regardless of menopausal status

3 years ago

Amid application tsunami, FDA's top cell and gene therapy leader to retire in March

3 years ago

Pandemic wait is over: FDA begins transition to in-person meetings in March

3 years ago

Covid public health emergencies to end in May, but FDA's EUA authority will continue

3 years ago

Oracle executive Troy Tazbaz named new FDA director of digital health

3 years ago

FDA approves Italy-based pharma's oral SERD for some breast cancer patients

3 years ago

Novavax gets ready to take another shot at Covid vaccine market with next season plans

3 years ago

Post-hoc analysis: EMA's CHMP rejects Ipsen's potential drug for rare genetic disease

3 years ago

FDA approves another indication for Keytruda, this time in the adjuvant NSCLC setting

3 years ago

First page Previous page 62 63 646566 67 68 Next page Last page